News >

Expert Sheds Light on Recent Advances in mCRC

Angelica Welch
Published: Thursday, Mar 29, 2018

Shubham Pant, MD

Shubham Pant, MD
The start of 2018 has brought about exciting developments in the treatment landscape of metastatic colorectal cancer (mCRC), explains Shubham Pant, MD.

The NCCN has updated its CRC guidelines, recommending a weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients. This was based on findings from ReDOS, a phase II dose-optimization study that compared the dose-escalation regimen with the standard dose of 160 mg of regorafenib daily. The 6-month overall survival (OS) rate was 66.5% in the dose-escalation arm versus 49.8% in the standard arm.1 The 12-month OS also favored the dose-escalation arm at 34.4% versus 26.7%, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication